Search results
Showing 901 to 915 of 1335 results for primary care
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England.
Show all sections
- Overview
- Introduction
- Section A: Technologies suitable for evaluation using the evidence standards framework
- Section B: Classification of digital health technologies
- Section C: Evidence standards tables
- Terms used in the evidence standards framework
- How to meet the standards
- Section D: Early deployment standards for evidence-generation programmes
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
Pressure ulcers: the management of pressure ulcers in primary and secondary care (CG29)
This guidance has been updated and replaced by NICE guideline CG179.
Evidence-based recommendations on Zio XT for detecting cardiac arrhythmias.
View recommendations for MTG52Show all sections
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)
NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .
Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
Evidence-based recommendations on Plus Sutures for preventing surgical site infection.
View recommendations for MTG59Show all sections
Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)
NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest
Evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)
NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .
This guideline has been updated and replaced by NICE guideline CG101.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.